GSK Hits Trifecta with Melanoma Drug, Dx Approvals
Genetic Engineering News
A total 250 previously untreated adult patients with BRAF V600E mutation-positive unresectable or metastatic melanoma were randomized to either drug. Mekinist was approved after Phase III data showed a statistically significant increase in PFS, to a ...
http://www.genengnews.com/gen-news-highlights/gsk-hits-trifecta-with-melanoma-drug-dx-approvals/81248422/
Genetic Engineering News
A total 250 previously untreated adult patients with BRAF V600E mutation-positive unresectable or metastatic melanoma were randomized to either drug. Mekinist was approved after Phase III data showed a statistically significant increase in PFS, to a ...
http://www.genengnews.com/gen-news-highlights/gsk-hits-trifecta-with-melanoma-drug-dx-approvals/81248422/
No comments:
Post a Comment